Gastroenteropancreatic neuroendocrine tumour disease+5
Not yet recruitingStudy on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment
Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment
- Disease:Gastroenteropancreatic neuroendocrine tumour diseasePeritoneal mesothelioma malignant+4
- Substances:DomvanalimabFluorouracil+3
France- Participants:18–64 years · 65+ years
- Substances:Domvanalimab
- Sponsor:Hospices Civils De Lyon







